摘要
目的 探讨促红细胞生成素对早产儿脑损伤的保护作用.方法 将2014年1月-2014年12月在我院治疗的88例早产儿随机分为对照组(44例)和观察组(44例),对照组患者采取常规三对症和三支持治疗,观察组患者在对照组基础上自患儿出生时予以重组人类基因促红细胞生成素进行治疗,并比较两组患儿的临床治疗效果.结果 出生时两组患儿神经行为测定评分比较差异无统计学意义(P〉0.05),治疗后两组患儿神经行为测定评分差异具有统计学意义(P〈0.05);观察组患儿社会行为、适应能力和精细动作评分均优于对照组,差异具有统计学意义(P〈0.05);观察组患儿神经系统影像异常发生率显著低于对照组,差异具有统计学意义(P〈0.05).结论 在常规治疗的基础上,对早产患儿采用重组人类促红细胞生成素,有助于改善患儿预后,减少脑损伤.
Objective To investigate protective effects of erythropoietin on brain injury in premature infants. Methods 88 preterm infants who were treated in our hospital from Jan. 2014 to Dec. 2014 were randomly divided into control group (n = 44)and observation group( n = 44 ). Infants in control group received routine three symptomatic and three support treatments. Infants in observation group received recombinant human gene erythropoietin treatment in ad- dition to routine treatment. Therapeutic effects were compared between the two groups. Results There was no signifi- cant difference on neurobehavioral assessment scores between the two groups at the time of birth ( P 〉 0.05 ). There was significant difference on neurobehavioral assessment scores between the two groups after treatment( P 〈 0.05 ). So- cial behavior,adaptive capacity and fine motor scores were all better in observation group than those in control group (P 〈 0.05 ). The incidence of neurological image abnormality in observation group was significantly lower than that in control group ( P 〈 0.05 ). Conclusion Recombinant human gene erythropoietin treatment based on routine treatment helps to improve the prognosis of premature infants and reduce brain damage.
出处
《医学新知》
CAS
2017年第4期356-358,共3页
New Medicine
基金
郑州市科学技术协会项目(编号:CZSYJJ14028)